Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eprotirome. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 15/20 | 1.00 |
| ▸ | THRA | P10827 | 15/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprotirome SCHEMBL29357083 | 1.00 | THRA (1.00) | THRATHRB | |
| SCHEMBL8230418 | 0.94 | THRA (0.88) | THRATHRB | |
| SCHEMBL2041087 | 0.91 | THRA (0.84) | THRATHRB | |
| SCHEMBL19498640 | 0.91 | THRA (0.83) | THRATHRB | |
| SCHEMBL23116502 | 0.90 | THRA (0.82) | THRATHRB | |
| SCHEMBL4962611 | 0.87 | THRA (1.00) | THRATHRB | |
| SCHEMBL4559561 | 0.87 | THRA (0.76) | THRATHRB | |
| SCHEMBL2043784 | 0.86 | THRB (0.78) | THRATHRB | |
| SCHEMBL8799273 | 0.86 | THRA (0.77) | THRATHRB | |
| SCHEMBL2427543 | 0.86 | THRA (0.75) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230372275-A1 | Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases | UNIV YALE (US) | 2023-11-23 | — | — | US | claimed |
| US-20230364044-A1 | Methods of Treating or Preventing Acute Respiratory Distress Syndrome | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-11-16 | — | — | US | claimed |
| EP-3644983-B1 | COMPOSITIONS AND METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES | UNIV YALE (US) | 2023-10-25 | — | — | EP | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| EP-3765059-A1 | METHODS OF TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME | Yale University (US) | 2021-01-20 | — | — | EP | claimed |
| US-20210008020-A1 | Methods of Treating or Preventing Acute Respiratory Distress Syndrome | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2021-01-14 | — | — | US | claimed |
| WO-2019005816-A1 | COMPOSITIONS AND METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES | YALE UNIVERSITY (US) | 2019-01-03 | — | — | WO | claimed |
| EP-2004593-B1 | IMPROVED CRYSTALLINE MATERIAL | KAROBIO AB (SE) | 2012-03-21 | — | — | EP | claimed |
| EP-2368873-A1 | Improved crystalline material | KARO BIO AB (SE) | 2011-09-28 | — | — | EP | claimed |
| US-20090239951-A1 | Crystalline Material | KARO BIO AB (SE) | 2009-09-24 | — | — | US | claimed |
| WO-2009080835-A1 | THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING | KARO BIO AB (SE) | 2009-07-02 | — | — | WO | claimed |
| EP-2004593-A1 | IMPROVED CRYSTALLINE MATERIAL | KARO BIO AB (SE) | 2008-12-24 | — | — | EP | claimed |
| WO-2007110225-A1 | IMPROVED CRYSTALLINE MATERIAL | KARO BIO AB (SE) | 2007-10-04 | — | — | WO | claimed |
| US-6806381-B2 | SUCH AS N-(3,5-DIBROMO-4-(4-HYDROXY-3-ISOPROPYL-PHENOXY)-PHENYL)-MALONAMIC ACID; FOR TREATMENT OF THYROID DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-19 | — | — | US | claimed |
| US-20030157671-A1 | Process for the preparation of aniline-derived thyroid receptor ligands | KARO BIO AB (SE) | 2003-08-21 | — | — | US | claimed |
| WO-2003039456-A2 | PROCESS FOR THE PREPARATION OF ANILINE-DERIVED THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008020-A1 | Methods of Treating or Preventing Acute Respiratory Distress Syndrome | TSHR, ADRB3, TRHR | THRB 6/4885THRA 4/4885 |
| US-20230372275-A1 | Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases | ADRB3, ADRB1, TGFBR2 | THRB 6/4885THRA 13/4885 |
| US-20090239951-A1 | Crystalline Material | HAO2, BMP2, NT5C3B | THRB 4758/4885THRA 4174/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | THRB 2/4885THRA 1/4885 |
| US-20230364044-A1 | Methods of Treating or Preventing Acute Respiratory Distress Syndrome | TSHR, ADRB3, TRHR | THRB 6/4885THRA 4/4885 |
| US-20030157671-A1 | Process for the preparation of aniline-derived thyroid receptor ligands | TSHR, THRA, THRB | THRB 3/4885THRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.